Quetta Acquisition Corp. (QETA) - 10-Q Summary for Period Ended June 30, 2024
Business Context and Reporting Period
Quetta Acquisition Corporation is a blank check company (SPAC) incorporated in Delaware on May 1, 2023, focused on effecting a business combination with financial technology companies in Asia (excluding China, Hong Kong, and Macau). The company completed its IPO on October 11, 2023, raising $69 million in gross proceeds. As of June 30, 2024, the company has not commenced operations and is in the process of identifying a target. On May 30, 2024, the company entered into a non-binding Letter of Intent (LOI) with a clinical-stage therapeutics company, extending the deadline to complete a business combination to January 11, 2025.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Three Months Ended June 30, 2024 |
|---|---|---|
| Net Income | $1,156,121 | $544,417 |
| Operating Loss | $(320,931) | $(197,702) |
| Interest Income (Trust Account) | $1,849,622 | $929,916 |
| Cash and Cash Equivalents | $334,332 | N/A |
| Investments in Trust Account | $72,356,146 | N/A |
| Working Capital Deficit | $(207,095) | N/A |
| Total Liabilities | $3,068,735 | N/A |
| Deferred Underwriting Fee | $2,415,000 | N/A |
Note: The company has no operating revenue. Net income is driven primarily by interest earned on the Trust Account.
Material Changes vs. Prior Period
- Trust Account Growth: Investments held in the Trust Account increased from $70,506,524 at December 31, 2023, to $72,356,146 at June 30, 2024, due to interest earnings of approximately $1.85 million for the six-month period.
- Operating Expenses: Formation and operational costs for the six months ended June 30, 2024, totaled $227,254, compared to zero in the prior year period (inception to June 30, 2023).
- Income Tax Provision: The company recorded a provision for income taxes of $383,682 for the six months ended June 30, 2024, primarily attributable to the interest income generated by the Trust Account.
- Redemption Value: The redemption value per share for common stock subject to possible redemption increased from $10.19 (Dec 31, 2023) to $10.40 (June 30, 2024).
Outlook, Risks, and Contingencies
- Going Concern: Management has determined that conditions raise substantial doubt about the company's ability to continue as a going concern. This is due to the working capital deficit and the requirement to complete a business combination by January 11, 2025, or face liquidation.
- Extension Terms: The company may extend the combination period by up to 21 months total. Extensions require the Sponsor to deposit $690,000 ($0.10 per share) into the Trust Account for each three-month extension.
- Proposed Transaction: The non-binding LOI with a clinical-stage therapeutics company is not a definitive agreement. No transaction is deemed to exist until definitive agreements are executed.
- Regulatory Risks: The Inflation Reduction Act of 2022 imposes a 1% excise tax on certain stock repurchases, which could apply to redemptions in connection with a business combination, potentially reducing cash available.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2024.
Investor Verification Checklist
- Definitive Agreement Status: Verify if a definitive merger agreement has been signed with the clinical-stage therapeutics target mentioned in the LOI.
- Extension Funding: Confirm the Sponsor's ability and intent to fund the $690,000 per extension deposit if the deal is not closed by the current deadline.
- Redemption Risk: Assess the likelihood of significant shareholder redemptions, which could impact the cash available for the transaction.
- Going Concern Resolution: Monitor for updates on the business combination timeline to resolve the substantial doubt regarding the company's ability to continue as a going concern.
- Internal Control Remediation: Review subsequent filings for plans to remediate the ineffective disclosure controls and procedures.